Arcutis Biotherapeutics, Inc. (ARQT) Revenue History
Annual and quarterly revenue from 2017 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
Revenue Growth Metrics
Revenue Breakdown (FY 2023)
ARQT's revenue distribution by segment and geography for fiscal year 2023
By Product/Segment
ARQT Revenue Analysis (2017–2025)
As of March 1, 2026, Arcutis Biotherapeutics, Inc. (ARQT) generated trailing twelve-month (TTM) revenue of $376.1 million, reflecting explosive growth of +81.5% year-over-year. The most recent quarter (Q4 2025) recorded $129.5 million in revenue, up 30.5% sequentially.
Looking at the longer-term picture, ARQT's historical revenue data shows a 3-year CAGR of +367.3%. The company achieved its highest annual revenue of $376.1 million in 2025, representing a new all-time high.
Revenue diversification analysis shows ARQT's business is primarily driven by Other Revenue (51%), and Product (49%). With over half of revenue concentrated in Other Revenue, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including UTHR (+10.6% YoY), ZLAB (+15.3% YoY), and AMRN (-6.2% YoY), ARQT has outperformed the peer group in terms of revenue growth. Compare ARQT vs UTHR →
Peer Comparison
Compare ARQT's revenue metrics with industry peers
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| ARQTCurrent | $376M | +81.5% | - | -3.3% | |
| UTHR | $3.2B | +10.6% | +16.5% | 46.9% | |
| ZLAB | $460M | +15.3% | +56.5% | -49.9% | |
| AMRN | $229M | -6.2% | -11.9% | -40.2% | |
| ALKS | $1.5B | -5.2% | +7.3% | 17.2% | |
| ADMA | $426M | +27.6% | +70.8% | 32.6% |
Historical Revenue Data
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $376.1M | +91.3% | $339.4M | 90.2% | $-12,227,000 | -3.3% |
| 2024 | $196.5M | +229.7% | $177.4M | 90.3% | $-128,397,000 | -65.3% |
| 2023 | $59.6M | +1517.1% | $54.6M | 91.6% | $-241,101,000 | -404.5% |
| 2022 | $3.7M | - | $2.9M | 79.5% | $-301,627,000 | -8183.0% |
| 2021 | $0 | - | $-763,000 | - | $-206,529,000 | - |
| 2020 | $0 | - | $-455,000 | - | $-136,645,000 | - |
| 2019 | $0 | - | $-195,000 | - | $-43,132,000 | - |
| 2018 | $0 | - | $0 | - | $-19,735,000 | - |
| 2017 | $0 | - | $0 | - | $-4,106,000 | - |
See ARQT's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ARQT Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare ARQT vs AGIO
See how ARQT stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is ARQT's revenue growth accelerating or slowing?
ARQT revenue is accelerating at +81.5% year-over-year, exceeding the 5-year CAGR of N/A. TTM revenue reached $376M. Growth momentum has increased versus prior periods.
What is ARQT's long-term revenue growth rate?
Arcutis Biotherapeutics, Inc.'s 5-year revenue CAGR of N/A reflects the sustained expansion pattern. Current YoY growth of +81.5% is above this long-term average.
How is ARQT's revenue distributed by segment?
ARQT reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2017-2025 are available for download. Segment mix reveals concentration and diversification trends.